• Enliven Therapeutics reached FDA alignment on the Phase 3 ENABLE-2 trial design for relcobatinib in previously treated chronic myeloid leukemia.
• Results have not been presented; the company plans to start the study before year-end 2026.
• The trial will test whether relcobatinib can deliver better patient response than standard second-generation targeted therapies in this setting.
• ENABLE-2 is designed as a head-to-head pivotal study, positioning relcobatinib for a potential registrational path if outcomes are positive.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610061605PR_NEWS_USPR_____LA65295) on October 06, 2026, and is solely responsible for the information contained therein.